Auxilium Pharmaceuticals agreed to pay $585 million in cash to purchase urology-treatment-maker Actient Holdings. The deal gives Auxilium access to Actient's testosterone replacement therapies and erectile dysfunction drug. The acquisition "creates a leading urology franchise with a diversified product portfolio and sales force leverage that is well positioned for growth of our current portfolio," Auxilium President and CEO Adrian Adams said.

Related Summaries